A More Promising Novel Rock Inhibitor-Fsd-c10

Y. Xin,I. Yu,C. Liu,Y. Li,L. Feng,X. Yang,Q. Wang,B. Xiao,G. Zhang,C. Ma
DOI: https://doi.org/10.1016/j.jns.2015.08.1128
IF: 4.4
2015-01-01
Journal of the Neurological Sciences
Abstract:Background: Although therapeutic potential of Fasudil in EAE is promising, there are some limitations. We have designed a novel ROCK inhibitor FSD-C10 that exhibits therapeutic potential in EAE. Objective: To observe the therapeutic effect of Fasudil and FSD-C10 on EAE, explore its mechanisms and compare the cell cytotoxicity and vasodilation between Fasudil and FSD-C10. Material and methods: Mouse EAE was induced by MOG35–55 immunization and treated with Fasudil or FSD-C10 in vivo. The study was approved by the Ethics Committee of Shanxi Datong University. BV-2 microglial and primary neurons were cultured in vitro for different experiments. Results: FSD-C10 via intranasal administration is able to delay EAE onset (p < 0.05) and declined maximum clinical score (p < 0.01) as compared with EAE control group. FSD-C10 induced neurite outgrowth of neurons and dendritic formation of BV-2 microglia and enhanced the production of neurotrophic factors BDNF, GDNF and NT3. The in vitro experiments showed cytotoxicity of FSD-C10 was lower than Fasudil. Both Fasudil and FSD-C10 exhibited the inhibitory efficiency of ROCK I and II. The inhibitory effect of ROCK I by FSD-C10 is relatively weak that may be related to insensitivity of vasodilation. Conclusion: FSD-C10 can easily be delivered via nasal administration and effectively suppresses EAE by inhibiting efficiency of ROCK and also by promoting neuroprotection. What's more, the cell cytotoxicity and vasodilation of FSD-C10 are relatively smaller as compared with Fasudil. (Grant: National NSF of China, 81272163;Research Project Supported by Datong Municipal Science and Technology Bureau, 2014105-1; Shanxi Scholarship Council of China, 2014-00023).
What problem does this paper attempt to address?